Clozapine efficacy in tardive dyskinesia in schizophrenic patients

Eur Arch Psychiatry Clin Neurosci. 1998;248(4):209-11. doi: 10.1007/s004060050039.

Abstract

Tardive dyskinesia (TD) is a long-term severe complication of antipsychotic treatment, with mean prevalence of 20-35%. The aim of this study was to evaluate effects of clozapine in severe TD. In an open trial seven patients with schizophrenia and severe TD were given clozapine for 6 months. Tardive dyskinesia severity was evaluated with AIMS and ESRS and schizophrenic psychopathology with PANSS. Clozapine mean dose at the end of the study was 392.86 mg/day. A mean reduction of 52% was observed in ESRS scores for TD. Two patients also had dystonic movements, and there was 50% reduction in one of them and complete remission in the other. There was also a 27% mean reduction in PANSS scores. Clozapine seems to be an alternative in the treatment of schizophrenic patients with severe TD.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antipsychotic Agents / administration & dosage
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / therapeutic use*
  • Clozapine / administration & dosage
  • Clozapine / adverse effects
  • Clozapine / therapeutic use*
  • Dyskinesia, Drug-Induced / complications
  • Dyskinesia, Drug-Induced / drug therapy*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Psychiatric Status Rating Scales
  • Schizophrenia / complications
  • Schizophrenia / drug therapy*

Substances

  • Antipsychotic Agents
  • Clozapine